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each year worldwide. They are among the top six
causes of death in low-income, middle-income and
high-income countries [1–3] and impose a huge
economic burden on the health services of all
countries. Respiratory tract infections can present
in adults and children in a variety of community
based and hospital settings and display a contextual
variety of clinical presentations from the minimally
symptomatic to the rapidly fulminant. This volume
of current opinions written by global experts con-
sists of 16 comprehensive articles, which review the
current literature and provide up to date infor-
mation on the epidemiology, diagnosis, manage-
ment and prevention of a range of pulmonary
infectious diseases. Advances in technology and
newer concepts for development of rapid diagnostic
tests and biomarkers for respiratory tract infections
are also reviewed.
Mass gatherings are events such as religious
festivals,music concerts, or sports events that attract
large numbers of people that far exceed the capacity
of routine health and public safety measures.
Managing such events requires providing for all
eventualities from infectious disease outbreaks to
security against bioterror attacks. The scale and
increasing frequency of these large international
events pose substantial risks to the spread of infec-
tious diseases, particularly the potential for rapid
transmission of bacterial and viral respiratory infec-
tions amidst substantial crowding and population
density. Three major mass gatherings events that
took place in 2012, the UEFA European Football
Championship known as ‘Euro 2012’ (8 June to
1 July 2012), The London Olympics (27 July to
12 August 2012), and the annual 2012 Hajj pilgrim-
age (24–29 October 2012), each attracted several
million people from all over the globe. These events
focused attention of the UKHealth Protection Agen-
cy, Ministry of Health of the Kingdom of Saudi
Arabia and the WHO, who together with interested
academics formally established the specialty ofmass-
gatherings medicine [4]. Memish and co-workersilliams & Wilkins. Unau
Health | Lippincott Williams & Wilk(pp. 192–197) review the literature on respiratory
tract infections at the Hajj where an estimated
4 million pilgrims visit Mecca and Madinah for at
least 2 weeks, living in close proximity to each other.
A largemajorityof themdevelopa rangeofupper and
lower bacterial and viral respiratory tract infections.
Pneumonia is a major cause of critical illness during
Hajj and pilgrims require hospitalization with high
associated mortality [5]. The authors emphasize the
basic practice of hand hygiene, face masks, and con-
tact avoidance, together with pretravel vaccination
to decrease the risk of acquiring respiratory tract
pathogens.
Recent advances are aimed at improving out-
comes and reducing the burden of diseases due to
community-acquired pneumonia (CAP), hospital-
acquired pneumonia (HAP), and ventilator-associ-
ated pneumonia (VAP). The review on CAP by
Muhammad Irfan et al. (pp. 198–208) reminds us
of the increasing recognition of the role of coinfec-
tions in CAP and strategies that include approval
of pneumococcal conjugate vaccines for at risk
adults will also be relevant to those attending mass
gatherings. The increasing global life expectancy is
likely to increase the elderly population, therefore
further research directed at CAP prevention in this
vulnerable population group in view of changing
demography and increased attendance at mass
gatherings is becoming important. Diego Viasusthorized reproduction of this article is prohibited.
ins www.co-pulmonarymedicine.com
CInfectious diseaseset al. (pp. 209–215) review recent literature on anti-
biotic resistance of respiratory pathogens, and the
advances in antibiotic therapy for CAP. Resistance
to the antibiotics commonly used in CAP is
frequently being documented over the years.
Several new antibiotics have been developed for
treating mild to moderate CAP, with promising
results. However, data regarding their efficacy and
safety in patients with severe CAP are lacking.
Antione Andremont et al. (pp. 216–228) highlight
the recent evidence on clinical epidemiology,
trends in bacterial resistances, diagnostic tools,
and therapeutic options in HAP, with a special
focus on VAP.
Matthew Bates et al. (pp. 229–237) review the
literature on autopsy studies from Africa and show
that lower respiratory tract infections are often the
most prevalent infectious disease causes of death in
Africa and are often associated with HIV coinfec-
tion. Pulmonary infections are particularly common
in the immunosuppressed host. Santino Capocci
and Marc Lipman (pp. 238–243) review the litera-
ture on the epidemiology, diagnosis, treatment and
prevention of HIV-related pulmonary infections
other than mycobacterial disease. They illustrate
that with widespread antiretroviral medication
usage, the pattern of HIV-associated pulmonary dis-
ease is changing. Although opportunistic infections
such as Pneumocystis jirovecii pneumonia still occur
in people not receiving antiretroviral therapy, HIV-
related infections are similar to those present in the
general population. Gauri Godbole and Vanya Gant
(pp. 244–250) review emerging threats, newer
modalities of diagnostic tests, and emerging treat-
ment options in patients with HAP. They inform us
that pulmonary infection remains the most fre-
quent infectious complication in the immunocom-
promised host and these complex infections are
often mixed, have atypical presentations and can
be due to multidrug resistant organisms.
Oana Ciofu et al. (pp. 251–258) discuss respir-
atory bacterial infections in cystic fibrosis patients
in whom chronic upper and lower respiratory tract
infections remain the single most prominent cause
of the increased morbidity and mortality. Continu-
ous microbiological surveillance is very important
in keeping the patients stable. The field of fungal
respiratory tract infections continues to evolve and
develop with many recent key advances. Gemma
Hayes and David Denning (pp. 259–265) highlight
key recent advances in fungal respiratory infections,
encompassing developments in epidemiology, diag-
nostics, and management; focusing on Aspergillus
spp., Pneumocystis jirovecii, and Cryptococcus spp. as
key pathogens. Their review reminds us that chal-
lenges remain in almost all areas, with further workopyright © Lippincott Williams & Wilkins. Unautho
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disease and address the increasing problem of azole
resistance.
Tuberculosis (TB) remains a major global public
health problem and although the global incidence
rate has slowly declined to an estimated 1.4 million
cases in 2011 [6], an alarming 630000 of multidrug-
resistant TB (MDR-TB) cases exist globally. The high-
est risk of MDR-TB among TB patients is in countries
of Eastern Europe, India, and South Africa. Alarm-
ingly, extensively drug-resistant TB has now been
reported from 84 countries, and the rising tide of
drug-resistant TB now poses major challenges for
global TB control. Four articles cover TB in this jour-
nal. Emanuele Pontali et al. (pp. 266–272) discuss
recent evidence on epidemiology, diagnosis, and
treatment of MDR-TB that has peaked in eastern
European countries such as Belarus, where a record
35.5%MDR-TB among new cases have been reported
from Minsk. Andrew Nunn et al. (pp. 273–279)
inform us in their review that there is an urgent need
to develop better regimens, to shorten treatment and
to effectively manage both drug-sensitive and drug-
resistant disease. Theydescribe thepromisingnewTB
drugdevelopmentportfolio andencouragingdataon
a number of TB drugs that are about to enter phase II
or phase III trials. Steve Lawn (pp. 280–288) reviews a
growing body of literature regarding the use of the
Xpert MTB/RIF assay for diagnosis of pulmonary TB
in a range of clinical settings, including among in-
patients, those with HIV coinfection and in children
with culture-positive disease, illustrating that there is
continued momentum regarding developments in
newTBdiagnostics. Next generation fully automated
molecular assays that use isothermal amplification
may in the future bemore readily implementedat the
point of care. Despite advances in TB diagnostics no
new TB biomarker has yet been identified [7]. Tapan
Mukerjee et al. (pp. 289–297) review advances in
nanotechnology for diagnosis and treatment of TB.
They cover the prospect of using nanotechnology for
the detection ofmycobacterial strains and nanotech-
nology-based drug delivery system for effective erad-
ication of mycobacterial infections.
Current standard diagnostic tests for acute and
chronic bacterial and viral infections are laborious
and time consuming. Currently, all ill patients pre-
senting with any form of respiratory tract infections
(CAP, HAP, VAP, or respiratory tract infections in
the immunosuppressed) are treated empirically
without an accurate diagnosis of the causative
microorganism and their antibiotic sensitivity pat-
terns. Correctly identifying the exact microorgan-
ism causing respiratory tract infections and treating
with appropriate antibiotics they are susceptible to
is essential, as morbidity and mortality rates arerized reproduction of this article is prohibited.
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Newer concepts on respiratory tract infections Zumlahigh. Respiratory tract infections remain difficult to
diagnose accurately as a broad range of pathogens
and opportunistic microorganism are involved in
their cause. Kate Reddington et al. (pp. 298–304)
review literature on recently available commercial
multiparametric molecular diagnostics tests for the
detection of respiratory tract infections. They
emphasize that reliability of the molecular drug
resistance markers chosen, the need for the quanti-
tative detection of some organisms, and throughput
are also important considerations for new technol-
ogy developers. As point of care diagnostic tools
become available so will an array of biomarkers of
disease activity, monitoring treatment efficacy and
cure. Mervyn Singer (pp. 305–309) reviews the
growing literature on biomarkers of sepsis and
suggests that new biomarkers will facilitate early
and accurate diagnosis, faster recognition of
impending organ dysfunction, optimal selection,
and titration of appropriate therapies, and more
reliable prognostication of risk and outcome. Travis
Henry and Kristopher Cummings (pp. 310–317)
summarize imaging findings of common parasitic
infections of the lung in the context of the life cycle
and pathophysiology of each parasite.
With recent exciting advances in technology,
the future promises a wide array of rapid point-of-
care diagnostics and biomarker tools on the horizon
that may become available within the next decade
and could revolutionize the management of respir-
atory tract infections, reducing mortality and mor-
bidity worldwide.Copyright © Lippincott Williams & Wilkins. Unau
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